检索结果-南通市图书馆

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

World Journal of Gastroenterology 2010年第35期16卷 4400-4409页

作者： Mosaburo Kainuma Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura yuichi tanabe Takeaki Satoh Toshihiro Maruyama Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Junya Shimono Shinji Shimoda Jun Hayashi Department of General Internal Medicine Kyushu University Hospital Department of Internal Medicine Nippon Steel Yawata Memorial Hospital Department of Medicine Hamanomachi Hospital The Center for Liver Disease Shin-Kokura Hospital Department of Medicine Fukuoka City HospitalYoshiduka-honmachi Center for Liver Disease National Hospital Organization Kokura Medical Center Department of Medicine Kitakyushu Municipal Medical Center Department of Gastroenterology Kyushu Medical CenterNational Hospital Organization Department of Medicine and Bioregulatory Science Graduate School of Medical ScienceKyushu University Department of Medicine and Clinical Science Graduate School of Medical SciencesKyushu University Saiseikai Yahata General Hospital Harunomachi Department of Medicine and Biosystemic Science Graduate School of Medical ScienceKyushu University

AIM:To analyze the efficacy and safety of a combination therapy of pegylated interferon(PEG-IFN) α-2b plus ribavirin(RBV) in older Japanese patients(65 years or older) infected with hepatitis C virus(HCV).METHODS:This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk.RESULTS:At 24 wk after the end of combination therapy,the overall sustained virological response(SVR) for genotypes 1 and 2 were 40.7% and 79.6%,respectively.The SVR rate decreased signif icantly with age in each genotype,and was markedly reduced in genotype 1(P<0.001).Moreover,the SVR was significantly higher in patients with genotype 1 who were less than 65 years(47.3% of 685) than in those 65 years or older(22.9% of 253)(P<0.001) and was higher in patients with genotype 2 who were less than 65 years(82.9% of 252) than in those 65 years or older(65.6% of 61)(P=0.004).When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV,the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older(P<0.001).Adverse effects resulted in treatment discontinuation more often in patients with genotype 1(14.4%) than in patients with genotype 2(7.3%),especially by patients 65 years or older(24.1%).CONCLUSION:PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage.

关键词： Hepatitis C virus Gerontology Pegylated interferon Ribavirin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Long-term lamivudine treatment for chronic,hepatitis B in Japanese patients:A project of Kyushu University Liver Disease Study

引用

World Journal of Gastroenterology 2006年第4期12卷 561-567页

作者： Norihiro Furusyo Hiroaki Takeoka Kazuhiro Toyoda Masayuki Murata yuichi tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Hideyuki Nomura Makoto Nakamuta Kazuhiro Takahashi Shinji Shimoda Koichi Azuma Hironori Sakai Jun Hayashi Department of General Medicine Kyushu University Hospital Department of Environmental Medicine and Infectious Diseases Graduate School of Medical Sciences. Kyushu University Fukuoka Japan Department of Medicine Fukuoka City HospitalFukuoka Japan Department of Internal Medicine Nippon SteelYawata Memorial Hospital Kitakyushu Japan Department of Medicine Yahata SaiseikaiHospital Kitakyushu Japan Department of Clinical Research NationalHospital Organization Kokura Hospital Kitakyushu Japan Department of Medicine KitakyushuMunicipal Medical Center Kitakyushu Japan Department of Internal Medicine ShinKokura Hospital Kitakyushu Japan Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University Fukuoka Japan Department of Medicine HamanomachiHospital Fukuoka Japan Department of Medicine and Biosystemic Science Graduate School of Medical Sciences Kyushu University Fukuoka Japan Department of Medicine and Clinical Science Graduate School of Medical Sciences Kyushu University Fukuoka Japan Department of Gastroenterology National Hospital Organization Kyushu Medical Center Fukuoka Japan

瞄准：与长期的肝炎 B 决定很多日本病人的长期的 lamivudine 治疗的功效。方法：在这回顾，多中心试用，有长期的肝炎 B 的 318 个日本病人每天为多达 36 收到了 lamivudine 的 100 mg (中部 21 ) 瞬间。Virological 反应是到浆液 HBV ... 详细信息

瞄准：与长期的肝炎 B 决定很多日本病人的长期的 lamivudine 治疗的功效。方法：在这回顾，多中心试用，有长期的肝炎 B 的 318 个日本病人每天为多达 36 收到了 lamivudine 的 100 mg (中部 21 ) 瞬间。Virological 反应是到浆液 HBV DNA 水平的衰落不到 3.7 木头 copies/mL。当浆液 HBV DNA 的再现在 treatment.RESULTS 期间铺平最小到超过 10 褶层， Virological 突破被定义：Lamivudine 在 6 瞬间在 318 个病人中的 86.8% 个生产了 virological 反应，在在 12 瞬间的 252 个病人中的 80.2% 个，在在 24 瞬间的 133 个病人中的 69.2% 个，并且在在 36 瞬间的 28 个病人中的 53.6% 个。向前逐步的逻辑回归分析证明 HBV DNA 铺平不到 6.8 木头 copies/mL ( P=5 瞬间的 3 个病人的100%。virological 突破与推迟的 virological response.CONCLUSION 在病人更经常显著地被发现：Lamivudine 治疗能在大多数测试日本病人压制浆液 HBV DNA。没有 HBeAg，长期的功效可能在基线在病人被看见，当肝硬化不在时，并且在有在 HBV 的衰落的病人， DNA 此后不久铺平治疗的开始。

关键词：乙型肝炎病毒日本肝疾病病理机制

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2:A project of the Kyushu University Liver Disease Study Group

引用

World Journal of Gastroenterology 2006年第5期12卷 784-790页

作者： Norihiro Furusyo Masaki Katoh yuichi tanabe Eiji Kajiwara Toshihiro Maruyama Junya Shimono Hironori Sakai Makoto Nakamuta Hideyuki Nomura Akihide Masumoto Shinji Shimoda Kazuhiro Takahashi Koichi Azuma Jun Hayashi Kyushu University Liver Disease Study Group Department of General Medicine Kyushu University HospitalFukuokaJapan Department of Medicine Fukuoka City HospitalFukuokaJapan Department of Internal Medicine Nippon Steel Yawata Memorial HospitalKitakyushuJapan Department of Medicine Kitakyushu Municipal Medical CenterKitakyushuJapan Department of Medicine Yahata Saiseikai HospitalKitakyushuJapan Department of Gastroenterology National Hospital Organization Kyushu Medical CenterFukuokaJapan Department of Medicine and Bioregulatory Science Graduate School of Medical SciencesKyushu UniversityFukuokaJapan Department of Internal Medicine ShinKokura HospitalKitakyushuJapan Department of Clinical Research National Hospital OrganizationKokura HospitalKitakyushuJapan Department of Medicine and Biosystemic Science Graduate School of Medical SciencesKyushu UniversityFukuokaJapan Department of Medicine Hamanomachi HospitalFukuokaJapan Department of Medicine and Clinical Science Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

瞄准：决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗，多中心研究回顾地被分析。方法：总共，有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三... 详细信息

瞄准：决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗，多中心研究回顾地被分析。方法：总共，有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三次皮下地收到 interferon-alpha。结果：总的来说持续的 virological 反应(SVR ) ，在浆液的定义同样无法发现的 HCV RNA，在治疗的结束以后的 24 wk，在 84.4% 显著地高，(146/173 ) 由 intention-to-treat 分析。在 SVR 的有效差量有或没有 ribavirin (46.9% 对 92.9%) 的中止在病人之间被发现，但是没有差别有或没有 ribavirin 的剂量减小在那些之间被发现。在 SVR 的有效差量也与 16 或更与不到 16 wk 和病人在病人之间被发现 ribavirin 治疗(34.8% 对 92.0%) 的星期。结论：24-wk 干扰素和 ribavirin 治疗为有 HCV 遗传型 2 的日本病人是高度有效的。SVR 的重要预言者是 ribavirin 治疗的继续多达 16 个星期。

关键词：病毒唑干扰素α 丙型病毒肝炎日本药物治疗

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Relationship between body surface area and ALT normalization after long-term lamivudine treatment

引用

World Journal of Gastroenterology 2005年第44期11卷 6948-6953页

作者： Makoto Nakamuta Shusuke Morizono yuichi tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Norihiro Furusyo Hideyuki Nomura Hironori Sakai Kazuhiro Takahashi Koichi Azuma Shinji Shimoda Kazuhiro Kotoh Munechika Enjoji Jun Hayashi Kyushu University liver Disease Study Group Department of Medicine and Bioregulatory Science Department of Medicine Department of Internal Medicine Department of Clinical Research Department of Environmental Medicine and Infectious Diseases Department of Gastroenterology Department of Medicine and Clinical Science Department of Medicine and Biosystemic Science

AIM: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation.METHODS: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249),two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA,as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT,albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed.RESULTS: For 1-year treatment, multivariate analysis revealed that BSA (P=0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBVDNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA(P = 0.0147) was the only factor for the biological effect,and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels.CONCLUSION: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.

关键词：乙型肝炎病毒治疗表面抗体 ALT

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Verification of the Effect of Improving Walking Ability on Hemiplegia by Using a Device for Reducing Muscle Tone

引用

Health 2020年第4期12卷 317-323页

作者： Hirofumi tanabe Akira Kusano Hiroshi tanabe Yoshifumi Morita yuichi Takata Department of Rehabilitation Shonan University of Medical Sciences Kanagawa Japan Department of Electrical and Mechanical Engineering Nagoya Institute of Technology Aichi Japan Department of Human Sciences Hokkaido Bunkyo University Hokkaido Japan

We evaluated the efficacy of the piston device simulating manual piston technique for hip joints (PTH) on 8 spastic hemiplegia patients suffering from a limited range of hip joint extension. Results confirmed rapid im... 详细信息

关键词： Device Gait Step Length Hemiplegia

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：